Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats

Drugs in R and D

Volumn 5, Issue 5, 2004, Pages 281-290

  Noa, Miriam ^a   Mendoza, Sarahí ^a   Más, Rosa ^a   Mendoza, Nilda ^a   León, Felipe ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; D 003; PREDNISONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE NECROSIS; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; FEMALE; FEMUR NECK; HISTOLOGY; HYPERTROPHY; MOLECULAR WEIGHT; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RAT STRAIN; TRABECULAR BONE;

ANIMALS; BODY WEIGHT; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FEMALE; NECROSIS; OSTEOPOROSIS; OVARIECTOMY; PREDNISOLONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 7244253206     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405050-00004     Document Type: Article

References (45)

1. Watts N. Osteoporosis: prevention, detection and treatment. J Med Assoc Ga 1997 Sep, 6
2. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932; 50: 137-95
3. Lukert B. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego (CA): Academic Press, 1996: 801-20
4. Lane N, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998; 27: 465-83
5. Legerton C. Corticosteroid-induced osteoporosis. J S C Med Assoc 2001; 97: 104-6
6. Weinstein R, Jilka R, Parfitt M, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998; 102: 274-82
7. Manolagas S. Birth and death of bone cells: basic regulatory mechanism and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37
8. Chavassieux P, Pastoreau P, Delmas P, et al. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporosis Int 1993; 3: 97-102
9. Weinstein R, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of biphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109: 1041-8
10. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002; 966: 73-81
11. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003; 15: 454-7
12. Oxtaf G, Oxlund H. Quantitative alterations of cortical bone in female rats after long term administration of growth hormone and glucocorticoid. Bone 1996; 18: 581-90
13. King C, Wein E, Gundberg C, et al. Effects of continuous glucorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996; 59: 184-91
14. Rude R, Gruber H, Oldam S. Cortisone-induced osteoporosis: effects on bone adenylate cyclase. Miner Electrolyte Metab 1993; 19: 71-7
15. Compston J. Prevention and management of osteoporosis: current trends and future prospects. Drugs 1997; 53: 727-35
16. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of biphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999; 14 Suppl. 2: 53-65
17. Plotkin L, Weinstein R, Parfitt M, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-74
18. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci U S A 1999; 96: 133-8
19. Staal A, Frith J, French M, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003; 18: 88-96
20. Mundy G, Garret R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-9
21. Bayraktar F, Oge A, Uyulgan B, et al. Atorvastatin increases femoral and vertebral bone strength in osteoporotic rats: endocrine abstracts. Vol 2. 192nd Meeting of the Society for Endocrinology; 2001 Dec 3-4; London. London: BioScientifica, 2001
22. Parhami F, Morrow A, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-7
23. Xu H, Watkins B, Seifert M. Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Calcif Tissue Int 1995; 57: 293-300
24. González L, Marrero D, Laguna A, et al. Inventors. Laboratorios Dalmer SA, assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa Patent 98-2744. 1998 Dec 30.
25. Menéndez R, Más R, Amor AM, et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001; 44: 299-304
26. Gámez R, Mendoza S, Más R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 2000; 61: 8-16
27. Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001; 62: 209-20
28. Castaño G, Mas R, Fernández L, et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs R&D 2002; 3: 337-48
29. Menéndez R, Mas R, Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002; 80: 13-21
30. Castaño G, Menéndez R, Mas R, et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003; 23: 193-203
31. Noa M, Más R, Mendoza S, et al. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exp Clin Res 2004; 30 (1): 35-41
32. Bagi C, Ammann P, Rizzoli R, et al. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 1997; 61: 336-44
33. Mosekilde L, Danielsen C, Knudsen B. The effect of aging and ovariectomy on the vertebral bone mass and biochemical properties of mature rats. Bone 1993; 14: 1-6
34. Irisa T, Yamamoto T, Miyanishi K, et al. Osteonecrosis induced by a single administration of low-dose lipopolysaccharide in rabbits. Bone 2001; 26: 641-9
35. Parfitt A, Drezner M, Glorieux F, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 1987; 2: 595-610
36. Ke HZ, Simmons HA, Pirie CM, et al. Droloxifene, a new estrogen antagonis/agonist prevents bone loss in ovariectomized rats. Endocrinology 1995; 136: 2435-41
37. Coro RM, Borrajero I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev Latinoam Patol 1996; 39: 9-10
38. Frame L, Hart R, Leakey JEA. Caloric restriction as an adaptative mechanism mediating resistance to environmental disease. Environ Health Perspect 1998; 106 Suppl. 1: 313-24
39. Eason JM, Dodd SL, Powers SK. Use of anabolic steroids to attenuate the effects of glucorticoids on the rat diaphragm. Phys Ther 2003; 83: 29-36
40. Nicholson SA, Campbell EA, Gillham B, et al. Recovery of the components of the hypothalamo-pituitary-adrenocortical axis in the rat after chronic treatment with prednisolone. J Endocrinol 1987; 113: 239-47
41. Dodd SL, Powers SK, Vrabas IS, et al. Interaction of glucocorticoids and activity pattern affect muscle function. Muscle Nerve 1995; 18: 190-5
42. Boss J, Misselevich L. Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 2003; 40: 345-54
43. Mankin HF. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326: 1473-9
44. Canalis E, Giustina A. Glucocorticoid induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001; 86: 5681-5
45. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop 2001; 386: 173-8